Literature DB >> 8075269

Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children.

K J Henrickson1, S M Kuhn, L L Savatski.   

Abstract

To determine the morbidity, costs, and epidemiological features of lower respiratory tract infections (LRIs) due to human parainfluenza virus types 1 and 2 (HPIV-1 and HPIV-2), we evaluated 1,213 children < 6 years of age who were seen for LRIs in the emergency room of the Children's Hospital of Wisconsin and/or were admitted to the hospital for LRIs during the fall quarter of 1991. The age, sex, race, and respiratory syndrome were recorded for each child; 158 patients (13%) had respiratory samples cultured for viruses and were followed clinically for the duration of their illness. Caucasian children had croup diagnosed more often than did African-American children (relative risk [RR] = 3.12; 95% confidence interval [CI], 2.43-4.00; P < .001), while African-American children more often had pneumonia (RR = 1.85; 95% CI, 1.36-2.5; P < .001). Forty-five of 70 viruses recovered were HPIV-1 (17 cases) or HPIV-2 (28 cases). Together these two viruses were recovered from 49% of children presenting with croup, 10% of those presenting with bronchiolitis, and 12% of those presenting with pneumonia. Gender- and race-associated differences were documented in the group of children infected with HPIV-2: specifically, this group included more girls than boys (RR = 1.99; 95% CI, 1.02-3.88; P < .04) and more Caucasian than African-American children (RR = 2.64; 95% CI, 1.05-6.63; P = .027). These data extrapolate nationally to approximately 250,000 emergency-room visits and approximately 70,000 hospitalizations due to HPIV-1 and HPIV-2, with a cost of $50 million for the former and $140 million for the latter.

Entities:  

Mesh:

Year:  1994        PMID: 8075269     DOI: 10.1093/clinids/18.5.770

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  42 in total

1.  Role of steroids in treatment of croup.

Authors:  K Chugh
Journal:  Indian J Pediatr       Date:  2000-01       Impact factor: 1.967

2.  Role of glucocorticoids in treating croup.

Authors:  R Somani; M F Evans
Journal:  Can Fam Physician       Date:  2001-04       Impact factor: 3.275

3.  National study of antibiotic use in emergency department visits for pneumonia, 1993 through 2008.

Authors:  Mark I Neuman; Sarah A Ting; Ahou Meydani; Jonathan M Mansbach; Carlos A Camargo
Journal:  Acad Emerg Med       Date:  2012-05       Impact factor: 3.451

4.  Two distinct human parainfluenza virus type 1 genotypes detected during the 1991 Milwaukee epidemic.

Authors:  K J Henrickson; L L Savatski
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Glucocorticoids in the treatment of croup: barking up the right tree.

Authors:  T P Klassen
Journal:  CMAJ       Date:  1998-11-03       Impact factor: 8.262

Review 6.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

7.  Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCR-enzyme hybridization assay.

Authors:  J Fan; K J Henrickson
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

8.  Systematic assembly of a full-length infectious clone of human coronavirus NL63.

Authors:  Eric F Donaldson; Boyd Yount; Amy C Sims; Susan Burkett; Raymond J Pickles; Ralph S Baric
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

9.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

10.  Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.

Authors:  Irina V Alymova; Garry Taylor; Toru Takimoto; Tsu-Hsing Lin; Pooran Chand; Y Sudhakara Babu; Chenghong Li; Xiaoping Xiong; Allen Portner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.